With a 77% revenue increase and a growing subscriber base, Hims & Hers Health Inc (HIMS) continues to innovate in ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy ...

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, ...

The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow ...

Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the ...

Reports Q3 revenue $401.6M, consensus $382.2M. “Improving momentum in both the Hims and Hers brands delivered another strong quarter of ...

Pre-earnings options volume in Hims and Hers Health is 1.2x normal with calls leading puts 8:5. Implied volatility suggests the market is ...

Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $20.36 which represents a slight increase of $1.53 or 8.13% from the prior close of $18.83. The stock opened at ...